Plasminogen activator inhibitor-1 (PAI-1) antigen plasma levels in subjects attending a metabolic ward: Relation to polymorphisms of PAI-1 and angiontensin converting enzyme (ACE) genes

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 10, 1997, Pages 2082-2087

  Margaglione, Maurizio ^b   Grandone, Elvira ^b   Vecchione, Gennaro ^b   Cappucci, Giuseppe ^b   Giuliani, Nicola ^b   Colaizzo, Donatella ^b   Celentano, Egidio ^b   Panico, Salvatore ^b   Di Minno, Giovanni ^a  

^a Clinica e Sperimentale   (Italy)

^b NONE

Author keywords

Cross sectional study; Genotype environment interaction; Inhibitor 1; Tissue plasminogen activator

Indexed keywords

ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BASE PAIRING; ENDOTHELIUM CELL; FEMALE; FIBRINOLYSIS; GENE DELETION; GENE INSERTION; GENETIC POLYMORPHISM; GENETIC REGULATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC ACTIVATION; MOLECULAR INTERACTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0031455723     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.10.2082     Document Type: Article

References (21)

1. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342:1076-1079.
2. Jansonn JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary heart disease. Circulation 1993;88: 2030-2034.
3. Ridker PM, Vaughan, DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993;341:1165-1168.
4. Ridker PM, Hennekens CH, Stampfer MJ, Manson J, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet. 1994;343:940-943.
5. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood. 1987;69:381-387.
6. Bachmann F. Molecular aspects of plasminogen, plasminogen activators and plasmin. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EG, eds. Haemostasis and Thrombosis. Edinburgh: Churchill Livingstone; 1994:575-614.
7. Chandler WL, Trimble SL, Loo SC, Mornin D. Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (tPA) and tPA/PAI-1 complex in plasma. Blood. 1990;76: 930-937.
8. Pralong G, Calandra T, Glauser MP. Plasminogen activator inhibitor-1: a new prognostic marker in septic shock. Thromb Haemost. 1989;61:459-462.
9. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem. 1993;268:10739-10745.
10. Margaglione M, Di Minno G, Grandone E, Vecchione G, Celentano E, Cappucci G, Grilli M, Simone P, Panico S, Mancini M. Abnormally high circulating levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke. Arterioscler Thromb. 1994;14:1741-1745.
11. Juhan-Vague I, Alessi MC, Joly P, Thirion P, Vague PH, Declerck PJ, Serredimigni A, Collen D. Plasma plasminogen activator inhibitor 1 in angina pectoris. Influence of plasma insulin, and acute-phase response. Arteriosclerosis. 1989;9:381-387.
12. Kluft C, Verhejen JH, Jie AFH, Rijken DC, Preston FE, Sue-Ling HM, Jespersen J, Aansen AD. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-plasminogen activator after trauma. Scand J Clin Lab Invest. 1985;54:605-601.
13. Margaglione M, Grandone E, Cappucci G, Colaizzo D, Giuliani N, Vecchione G, d'Addedda M, Di Minno G. An alternative method for PAI-1 promoter polymorphism (4G/5G) typing. Thromb Haemost. 1997;77:605-606.
14. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation. 1993;87:1969-1973.
15. Vaughan DE, Lazos SA, Tong K, Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endotelial cells: a potential link between the renin-angiotensin system and thrombosis. J Clin Invest. 1995;95:995-1001.
16. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Sourbrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounts for half of the variance of serum enzyme levels. J Clin Invest. 1990;86:1343-1346.
17. Coxterousse O, Allegrini J, Lopez M, Alheuc-Gelas F. Angiotensin I-converting enzyme in the human circulating mononuclear cells: genetic polymorphism of expression in T lymphocytes. Biochem J. 1993;290:33-40.
18. Margaglione M, Celentano E, Grandone E, Vecchione G, Cappucci G, Giuliani N, Colaizzo D, Panico S, Mancini FP, Di Minno G. Deletion polymorphism of the angiotensin converting enzyme gene in patients witji a history of ischemic stroke. Arterioscler Thromb Vasc Biol. 1996;16:304-309.
19. Margaglione M, Di Minno G, Grandone E, Vecchione G, Celentano E, Cappucci G, Mancini FP, Postiglione A, Panico S, Mancini M. Plasma lipoprotein(a) levels in subjects attending a metabolic ward. Arterioscler Thromb Vasc Biol. 1996;16:120-128.
20. Margaglione M, Di Minno G, Grandone E, Vecchione G, Celentano E, Cappucci G, Giordano M, Grilli M, Simone P, Fusilli S, Panico S, Mancini M. Raised plasma fibrinogen concentrations in subjects attending a metabolic ward: relation to family history and vascular risk factors. Thromb Haemost. 1995;73:579-583.
21. Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (Dipeptyl carboxypeptidase 1). Nucleic Acids Res. 1992;20:1433.